Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Delivery: Enteral Route
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Prevention of Further Absorption of Poison
Opioid Receptors: Overview
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
ZNRF3 and RNF43 are active monomeric E3 ubiquitin ligases that self-associate.
Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.
Diacylglycerol kinase ζ in B lymphocytes supports CD40-mediated immune synapse formation, mTORC1 signaling, and plasma cell fate.
The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma.
Virion display reveals MD-1 as an endogenous agonist for the orphan receptor GPRC5B.
Related Experiment Video
Updated: Jun 18, 2025

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Enhancing naloxone.
1Science Signaling, AAAS, Washington, DC 20005, USA.
A novel negative allosteric modulator targeting the mu-opioid receptor was found to boost naloxone effectiveness. This finding may lead to improved opioid overdose reversal strategies.
More Related Videos
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- The mu-opioid receptor is a key target in pain management and addiction.
- Naloxone is a critical opioid antagonist used for overdose reversal.
- Developing strategies to enhance naloxone's efficacy is crucial for public health.
Purpose of the Study:
- To investigate the effect of a negative allosteric modulator (NAM) of the mu-opioid receptor on naloxone's efficacy.
- To explore novel therapeutic approaches for opioid overdose.
Main Methods:
- Pharmacological assays were used to characterize the NAM.
- In vitro and in vivo models were employed to assess the interaction between the NAM and naloxone.
- Opioid receptor binding and signaling pathways were analyzed.
Main Results:
- The identified NAM selectively binds to the mu-opioid receptor.
- Co-administration of the NAM significantly enhanced the efficacy of naloxone in reversing opioid-induced effects.
- The NAM potentiated naloxone's ability to displace agonists from the receptor.
Conclusions:
- Negative allosteric modulation of the mu-opioid receptor represents a promising strategy to improve naloxone's effectiveness.
- This approach could lead to more potent and rapid reversal of opioid overdose.
- Further research is warranted to explore the clinical potential of this therapeutic combination.

